Summary & Overview
HCPCS J9321: Injection, epcoritamab-bysp, 0.16 mg
HCPCS Level II code J9321 designates the injectable oncology biologic epcoritamab-bysp at 0.16 mg per unit. As a medication administration code for a targeted cancer therapy, J9321 is relevant to hospital outpatient departments, infusion clinics, and physician offices nationally where biologic anti-cancer agents are administered. Its use affects pharmacy and medical benefit coordination, prior authorization workflows, and coverage determinations for high-cost specialty drugs.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for epcoritamab-bysp administration, typical sites of service, and how the code is applied in billing. The publication also outlines benchmarks and coverage considerations, relevant modifier practices when available, and policy or reimbursement updates affecting specialty injectable biologics.
This summary supplies practical reference information for revenue cycle, clinical billing staff, and policy analysts who manage specialty oncology drug billing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9321 represents an injection of epcoritamab-bysp, dosed at 0.16 mg per billed unit. This code is used to report administration of the specified oncology biologic.
Service Type: Injectable biologic therapy
Typical Site of Service: Outpatient infusion clinic or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with relapsed or refractory diffuse large B-cell lymphoma receives outpatient administration of subcutaneous epcoritamab-bysp (a CD3xCD20 bispecific monoclonal antibody) dosed in 0.16 mg increments for billing as J9321. The patient presents to an oncology infusion clinic or designated oncology outpatient department. Pre-infusion evaluation includes weight and vital signs, review of recent labs (CBC, CMP), assessment for active infections, and documentation of indication and prior therapies. The medication is prepared by pharmacy under sterile technique and dispensed as the appropriate syringe/vial quantity; J9321 is reported per 0.16 mg increment administered. During the visit, nursing monitors for infusion- or injection-related reactions including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity (ICANS). Observation time post-injection varies by institutional protocol but commonly ranges from 1–4 hours for initial doses. Documentation includes drug name and dose, lot number, route (subcutaneous), site of administration, patient tolerance, and any immediate interventions. Subsequent doses follow a scheduled outpatient oncology regimen with similar documentation and monitoring requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |